home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  July 22, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 456 active entries

SciTech Development LLC

281 Kercheval Avenue
Grosse Pointe Farms, 48236
United States of America, Michigan

Phone: +1-313-263-4887


SciTech Development, LLC

A clinical-stage, specialty oncology pharmaceutical company

Revolutionizing how safe and promising yet challenged drugs

can be delivered to kill cancer



ST-001 nanoFenretinide: Lead Drug Candidate and Clinical Trial Ready

Through a combination of innovative science and advanced nanotechnology, SciTech has developed ST-001nanoFenretinide, a patented formulation that is clinical trial ready for T-cell lymphomas (a form of non-Hodgkin lymphoma). 


Problem: Low Drug Bioavailability Severely Limits Clinical Use

Many cancer drugs have low bioavailability (absorption) due to water insolubility. This results in sub-therapeutic dosing levels and insufficient amounts of the drug delivered to the cancer cells. Increasing the dose can lead to unacceptable toxicity levels and side effects. Fenretinide’s low bioavailability presented challenges for use in cancer and remained unsolved - until now.


Solution: An Effective Delivery Platform and ST-001 nanoFenretinide

ST-001 is a nanoparticle combination of fenretinide and biocompatible phospholipids, allowing rapid infusion (IV) of high-dose fenretinide to solve bioavailability challenges, avoid triglyceride (or fatty) toxicity, and            optimize therapeutic efficacy. 

 Overcomes drug delivery and bioavailability challenges seen with fenretinide

 Safely achieves therapeutically effective dosing

 Avoids toxic side effects seen with other delivery systems and formulations

 Delivers a 6-fold higher formulation strength than conventional IV formulations

 Safely delivers at least a 15-fold higher concentration of fenretinide to target cancer cells than other reference formulations

 Enables potential use in numerous other cancers types

ST-001 Clinical Trials

  FDA approved, accelerated Phase 1a/b clinical trial for T-cell lymphoma

  Clinical trials beginning in Q4/2023, with several major medical centers

  Institutional Review Board (IRB) approvals: Required for patient recruiting

 Successfully manufactured cGMP clinical supply of ST-001 with our contract drug manufacturing partner

SDP: SciTech Nanoparticle Drug Delivery Platform

 Patented nanoparticle drug delivery platform (SDP) aims to solve bioavailability and toxicity challenges

  Uses safe phospholipids to maintain or improve safety profiles

 Can be utilized to increase SciTech’s product pipeline in various other cancers

 May be used to formulate other similarly challenged therapeutic agents



Selected Categories:
Product Company   Service Company
- General
- General
- Research

Last update of this entry: October 24, 2023

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.